Memory loss is the most prominent clinical aspect of Alzheimer’s Disease. Ultimately, therapeutic interventions will only be valuable to patients if they can prevent memory loss or restore memory function. To further assist our clients with assessing the efficacy of their Alzheimer treatments, reMYND has complemented it’s offering with cognitive performance tests in it’s proprietary Tau models.
In addition to measuring cognitive performance in our APP-london and APP-ldxPS1 models we now have complemented our offering with cognitive testing in our Tau.P301L and Tau.P301S models. Both models show a cognitive deficit before any neurofibrillary tangles can be detected (figure 1 and figure 2).
Both the Tau.P301L and the Tau.P301S models feature progressive hyperphosphorylation of Tau with age which leads to a profound NFT-like pathology in the brainstem, spinal cord, cortex and hippocampus regions and have impaired synaptic plasticity as measured by Long Term Potentiation and Long Term Depression at young age.
Figure 1: Morris Water Maze with 3 month old Tau.P301S and age-matched non transgenic control animals (N = 17 per group). Learning curve over four consecutive training days with four trainings per day (left). Quadrant analysis during the probe trial (left), north east (NE) is the target quadrant.
Figure 2: Cognitive performance of 5 month old Tau.P301L and non transgenic control animals measured with the Passive Avoidance test (N = 17 per group).
For more information on reMYND’s transgenic mouse models, please contact Bart Roucourt, CRO Manager.